As the current management of BPH/lower urinary tract symptoms by traditionally involved pharmacological agents such as 5alpha-reductase inhibitors and a 1 -adrenoceptor antagonists is suboptimal, there is definite need of new therapeutic strategies. There is ample evidence in literature that suggests the role of estrogens in BPH development and management through the different tissue and cell-specific receptors. This article reviews the beneficial actions of selective estrogen receptor modulator (SERM) and ERbselective ligands, which have been demonstrated through in vitro studies using human prostate cell lines and in vivo animal studies. SERMs have anti-proliferative, anti-inflammatory and pro-apoptotic mechanisms in BPH, and also act by inhibiting various growth factors, and thus represent a unique and novel approach in BPH management directed at estrogen receptors or estrogen metabolism.
INTRODUCTION
BPH is a common urological problem of aging males. It occurs in about 10% of men below the age of 40 and increases to about 80% by 80 years of age. 1 Clinical BPH is a benign enlargement of the prostate, which results in voiding urinary difficulties that may, sometimes, significantly impair the quality of life in older patients. 2 Currently, the favored treatment option for lower urinary tract symptoms due to BPH/BPE is medical therapy with a-blockers that help in alleviating the symptoms by reducing the stromal tone, and androgen suppressors that counteract the static component. These two approaches give modest improvement in objective parameters such as peak flow rate and prostate volume regression but on discontinuation of these agents, both disease as well as symptoms tends to recur. As the present medical therapies are focused mostly on relief of lower urinary tract symptoms and have some impact on benign prostatic enlargement, there is a definite need to find novel therapies that affect the basic pathophysiology of BPH.
Estrogens and selective estrogen receptor modulators (SERMs) have been shown to affect the prostatic cellular and stromal proliferation. 3 The current review intends to examine the potential role of SERMs in management of BPH.
METHODS
A PubMed search was conducted with the keywords 'estrogens in BPH'; 'selective estrogen receptor modulators'; 'tamoxifen in BPH'; 'raloxifene'; and 'phytoestrogens' to identify published articles on role of estrogens in BPH. The terms 'SERM in prostate diseases'; 'BPH pathogenesis'; 'estrogen receptors'; 'apoptosis in BPH'; and 'inflammation in BPH' were also searched out in PubMed. In addition, the 'related articles' search option on PubMed and references of relevant articles were also looked for with knowledge of experimental study done on same subject at our research center was utilized. At the end of literature research, the most relevant articles were selected for the discussion of role of SERMs in BPH in this review.
ESTROGENS AND ITS RECEPTORS: ROLE IN BPH
Though BPH typically manifests in later stage of life when androgen levels are declining, androgens are thought to be prerequisites for the development of BPH. 4, 5 With advancing age, plasma androgen levels decrease gradually while estrogen levels remain constant or decrease slightly, resulting in increased ratio of estrogen to androgen in plasma. [4] [5] [6] In elderly men, the ratio of free estradiol (E2) to free testosterone (T) was observed to increase by up to 40%. 7, 8 Although estrogen level remains fairly constant in the epithelium during the entire age range, they get increasingly accumulated in the stroma with advancing age. 9 This could be of patho-physiological importance for BPH development.
Various animal studies have highlighted that BPH occurs with the stimulation of the prostate by estrogens. 10, 11 An animal model of BPH demonstrated that in castrated dogs, treatment with estradiol alone without androgens led to development of squamous prostate epithelial metaplasia, 12 whereas estradiol when given along with androgens resulted in glandular prostatic hyperplasia. 10, 12 These studies clearly indicated that estrogens might exert a synergistic effect with androgens in inducing prostatic hyperplasia.
Climent et al. 13 investigated the direct effects of estradiol on the proliferation of BPH-derived prostate cells in culture. Estradiol (10 À 7 and 10 À 6 M) moderately increased the proliferation of stromal cells in culture without affecting the proliferation of epithelial cells. Symptomatic BPH patients reveal a 33% increase in stromal volume compared with healthy controls.
14 These findings support the fact that estrogens may have an important role in the pathogenesis of BPH predominantly for the stromal component.
Estrogens exert their effect on target gene expression by binding to specific intracellular estrogen receptors (ERs). These receptors, which act as hormone-inducible transcription factors, are of two distinct types ERa and ERb. By mediating estrogen signaling and transcription, these receptors drive growth, proliferation, differentiation and many other cellular processes.
ERa and ERb have specific expression patterns and distinct phenotypes, leading to their different biological functions. In the normal prostate and BPH, ERa is localized to stromal cells, and estrogen mediates its effects on the prostate epithelium through paracrine pathways. 13, 15, 16 ERa acts as a mediator of cell proliferation while ERb acts in opposite way by inhibiting ERamediated proliferation. [17] [18] [19] [20] [21] [22] [23] ERb-MODULATION IN BPH: POTENTIAL BENEFICIAL EFFECTS SERMs are generally nonsteroidal compounds that affect ER signaling in the tissue-specific way. The SERMs exert selective effects on various tissues that are estrogen sensitive, including the prostate. These SERMs may act as either agonists or antagonists depending upon the site of action, unlike the estrogens, which are uniformly agonists, and the pure anti-estrogens, which are uniformly antagonists. 24 There is sufficient evidence which suggests that the beneficial effects of estradiol are mediated by ERb, [25] [26] [27] while ERa might be responsible for aberrant proliferation. Therefore, it would be highly desirable to have agents that are capable of neutralizing the ill-effects of increased estradiol signaling in the aged prostate by upregulating the ERb expression and downregulating ERa receptors.
Different natural and synthetic ERb-selective ligands have been identified, 28, 29 which provide the beneficial effects of estrogens while avoiding their unwanted side effects. The b-selective SERMs significantly increased the transcript and protein levels of ERb and markedly reduced those of ERa in BPH stromal cells. 3 Hence, SERMs have the potential of effectively controlling prostate hyperplasia through favorable modifications in intraprostatic stromal-epithelial cross-talk by increasing signaling through ERb and simultaneously decreasing signaling through ERa. 3 Various studies have suggested that this targeted approach for treating BPH through the use of SERMs, and more specifically ERb agonist, would be of benefit. 26, 30 Many epidemiological and experimental researches have shown that dietary estrogens are beneficial to men's health. 29, 31, 32 This may be evident from the fact that men living in Western nations have higher incidence of prostate cancer and BPH, plausibly because of their lower dietary phytoestrogen intake, as compared with their counterparts in Asian countries. [33] [34] [35] Many of these phytoestrogens are found to display ERb receptor selectivity, especially compounds whose core structures have isoflavone or flavones group. Genistein, a naturally occurring SERM which shows 22-fold selectivity for ERb, is an isoflavone usually found in soy. 36 Liquiritigenin (component of an herbal extract) is another natural ERb-selective (20-fold) phytoestrogen, and the new ERbselective ligands may be synthesized using its pharmacophore. 37 Different types of ERb-selective agonists have been classified as 1. Agents which have higher binding affinity to ERb receptors as compared with a-receptors, 38 for example, ERB-041 (WAY-202041) 2. Agents that bind to both ERs with equal affinity, but only activate transcription with ERb, for example, MF101, nyasol and liquiritigenin 3. Agents which have both characteristics of greater binding and transcriptional activity with ERb, for example, diarylpropionitrile.
ERb-MODULATION IN BPH: HOW DOES IT WORK?
Anti-proliferative response The activation of ERb leads to an anti-proliferative response that is not influenced by alterations in systemic androgen levels or activation of ERa, as demonstrated by using tissue recombination technology. Using intact aromatase knockout mice, a study demonstrated that the administration of an ERb-specific agonist abrogates existing hyperplastic prostatic pathology. 26 In our study, 3 we found that the viability and proliferation of human BPH-derived stromal cells was reduced dose dependently by SERMs at concentration ranging from 0.625 to 10mM. 4-Hydroxytamoxifen most effectively and significantly reduced stromal cell viability followed by DL-2-[4-(2-piperidinoethoxy) phenyl]-3-phenyl-2H-1-benzopyran (BP) and tamoxifen, which were almost equipotent. On the other hand, all these SERMs were nearly equipotent in reducing the proliferation of BPH stromal cells.
In a study by Yang et al., 39 raloxifene antagonized the estrogenstimulated proliferation in cultured prostate stromal cells. Estradiol (E2), when used alone, induced the proliferation of the WPMY-1 (stromal cell line) by 31% (Po0.05). However, tamoxifen, raloxifene and finasteride antagonized the proliferation of these cells when used along with E2 by 16, 17 and 25% respectively (Po0.05), showing that SERMs can have additive effects over and above the one exerted by finasteride.
Inhibition of growth factors
Various growth factors such as transforming growth factor-b1, fibroblast growth factor and insulin-like growth factor-1 (IGF-1) are the key regulators of cell proliferation and extracellular matrix turnover. 40 These agents are all subject to alteration with age and are potential triggers for the initiation of stromal hyperplasia.
Prostatic IGF-1 gene expression has been correlated positively with both BPH and prostate cancer, 41 while epidermal growth factor receptor (EGFR) protein has been localized predominantly in BPH tissues. 42 We found that ormeloxifene (a SERM) significantly downregulated IGF-1 expression, whereas hydroxytamoxifen and tamoxifen also reduced EGFR level in BPH stromal cells. 3 However, BP not only decreased IGF-1 and EGFR transcript levels, but also concurrently increased the transcripts of growth regulatory peptide TGF-b1, whose impaired function has been directly correlated with pathogenesis of BPH. 43 Thus, SERMS may have potential to directly affect the levels of growth factors.
Anti-inflammatory effects Prostatic inflammation may be one of the important factors in the pathogenesis of human BPH. 44, 45 BPH nodules are thought to be associated with chronic inflammatory infiltrates, mainly composed of activated T-cells and macrophages. [46] [47] [48] These inflammatory cells produces cytokines (IL-2 and IFNg) that may support fibromuscular growth in BPH. 49 While ERa have been shown to induce inflammation, ERb has been suggested to have antiinflammatory effects. Fispemifene, 50 a novel SERM, showed antiinflammatory action in the dorsolateral prostate by decreasing the number and density of inflamed acini. As reported by Sharma et al., 51 Sprague-Dawley rats on soy diet were found to have reduced risk of chronic prostatitis and this mechanism may be responsible for the lower incidence of BPH in Asian men consuming soy. 52, 53 Though there are sufficient data that the regular consumption of soy prevents the obstructive voiding of BPH, confirmatory clinical evidence is still lacking.
Pro-apoptotic effects ERb also induces apoptosis in the prostate in addition to having anti-proliferative effect, 25 and mechanism of ERb action is mediated by tumor necrosis factora (TNFa) and is androgen independent. 54 In our study 3 we found that BP sensitizes BPH stromal cells to caspase-8-mediated apoptosis though extrinsic pathway by significantly upregulating the mRNA levels of TNF family death receptors and its ligands (Fas/FasL). Human BPH
studied, which revealed the apoptosis of mainly the stromal cells in BPH tissue, which was maximum in case of hydroxytamoxifen and minimum in case of ormeloxifene. Ki-67 labeling was notably reduced in SERM-treated BPH explants as compared with control.
Ex vivo data by Glienke et al. 55 clearly demonstrate that the administration of hydroxytamoxifen at concentrations from 10 to 20 mM induces apoptosis in human prostate stromal cells. The induction of apoptosis was more effective with hydroxytamoxifen than with tamoxifen though clinical studies could not confirm the effects of tamoxifen treatment on BPH.
ERb agonists induce apoptosis in different cells of estrogendeficient aromatase knockout mice, that is, luminal, prostatic stromal and basal epithelial cells. 54 ERb agonists fail to respond in the TNFa knockout mice, demonstrating TNFa-induced apoptosis in the stromal cells. In addition to the direct effect of ERb agonists on the stromal nodules of BPH, they also disrupt stromal-epithelial interactions, which are important for proliferation and differentiation of prostatic epithelial cell. 56 By targeting the stromal component, the aberrant cycle of paracrine signaling breaks, and thus ERb agonists may affect both stroma and epithelial cells, explaining their potential therapeutic use. The pathway of apoptosis induced by ERb agonist is different from that of castration. While ERb agonists induce apoptosis via activation of caspase-8, castration does so by using caspase-9 57 and as opposed to apoptosis induced by castration, ERb agonists cause apoptosis in both the androgen-dependent or -independent cells ( Figure 1 and Table 1 ).
ERb MODULATION: VALIDATION IN ANIMAL BPH MODEL AND HUMAN CELL LINES
Recently, responses of ERb-selective ligands have been demonstrated in various animal studies. Norman 58 proved in rodent prostate models that involution of the ventral prostate occurs with the use of ERb-selective ligands. Also with the administration of an ERb-specific agonist, prostatic epithelial hyperplasia ablates whereas an ERa-specific agonist did not produce any such effect as demonstrated in studies with knockout mice models. 36 These findings suggest that ERb-specific agonists have sufficient potential to be used as new agents for the pharmacological intervention and management of prostatic hyperplasia.
Our in vivo studies in rat 3 indicated that irrespective of the molecular structure and mechanism of action, the SERMs universally and significantly reduce prostate weight. This response was better in combination with a 5a-reductase inhibitor, finasteride. We found that the ventral prostate of adult mature rats receiving tamoxifen, BP and ormeloxifene each at 1.0 mg kg À 1 dose for 21 days regressed significantly by 37%, 32%, 36% respectively.
Histological investigations on human BPH tissue 3 revealed that finasteride, when used alone, effectively reduced acinar diameter but cause marginal decrease in epithelial cell height, while SERMs caused extreme thinning of epithelium along with dilation of acini. This was accompanied with complete disappearance of epithelial invaginations, a feature most prominently seen in BPH tissue. However, when both finasteride and SERM were used in combination, a substantial reduction in both epithelial cell height and acinar diameter was evident. Thus, SERMs can potentiate the action of 5-a reductase inhibitors for a better response.
Yang et al. 39 studied the effect of raloxifene on prostatic stromal hyperplasia in rats. Quantitative analysis of rat prostate indicated that in the tamoxifen and raloxifene groups, the number of acini was decreased, and the appearance of epithelial cells changed from columnar to flat or low columnar type. In addition, the smooth muscle cell layer that surrounds the acini became thinner. Further improvement had not been seen with combination of finasteride and raloxifene compared with that of raloxifene alone. Yang showed that both the proliferation of prostatic stromal and epithelial cells could be inhibited by SERMs. The immunohistochemistry staining results showed that raloxifene was found to be a more potent agent that caused reversal of smooth muscle cell thickness. Herein, authors provide the strong evidence that raloxifene may have a beneficial role in the rat prostate hyperplasia. Figure 1 . Proposed mechanisms involved in beneficial effect of selective estrogen receptor modulator (SERMs) in BPH. EGFR, epidermal growth factor receptor; IGF-1, insulin-like growth factor-1; TNF-a, tumor necrosis factor a; TGFb, tumor growth factor.
Selective estrogen receptor modulators M Garg et al
Gene expression profiling along with studies in bERKO mice further enhanced our knowledge about molecular basis of ERb-mediated effects within cells and their importance in pathophysiology of BPH (Table 2) .
Different theories emphasizing the causative mechanism of BPH pathogenesis have been described in literature. In dihydrotestosterone hypothesis, it is postulated that castration in men before puberty lead to failure of BPH to develop. 59 Embryonic reawakening theory 60 enumerates reawakening of the embryonic induction potential of prostatic stroma through involvement of various mechanisms including growth factors such as transforming growth factor. 61 Last, in stem cell theory, BPH develops through stem cells number increase or in clonal expansion of transit or amplifying cells. 62 As discussed, SERMs have beneficial effects on BPH by modifying the growth factors. More recently Hu et al. 63 in their experimental work cultured stem/progenitor cells from normal human prostate using a prostasphere assay and showed that these cells express high levels of ER including ERa, ERb and GPR30 but not androgen receptors. These stem cells had a proliferative response on exposure to 1 nM estradiol-17b and are specific targets for estrogen action in the prostate. On stimulatory response of these receptors, augmented signals alter the normal cell proliferative and apoptotic pathways in a number of estrogentarget tissues including prostate. This molecular aspect highlights the potential for SERMs in targeting diseased stem cells by modifying these signals for the treatment of prostate diseases.
Ho and Habib
64 in their recent study discussed that the estrogens effect the prostate through various mechanisms, such as aromatase expression and apoptosis, and via prostaglandin E2 and SERMs can influence these intraprostatic estrogen levels and are potential therapeutic targets for the treatment of BPH.
With these studies, there is ample evidence that SERMs may be of benefit for the treatment or prevention of BPH, and it is high time to explore these agents through clinical prospective trials to ascertain their efficacy in treatment of prostatic hyperplasia, subject to satisfactory pharmacokinetic and toxicity testing. 65, 66 LIMITATIONS AND APPROACHES FOR IDENTIFYING ERb-SELECTIVE LIGANDS The ERb through regulating different physiological functions has a potential of becoming therapeutic target for various pathological states. However, the clinical application of SERMs for the treatment of BPH may not be as simple as it appears to be, as there are several other aspects that can complicate this issue, including the variability of ERa and ERb expression in prostate diseases. Because of the structural characteristics and similar ligand-binding cavity of ERa and ERb, it has been difficult to identify ERb ligands with high affinity, potency and selectivity. 67 Thus, it is challenging to develop ERb-selective ligands for therapeutic use and this is one of the reason for the hinderance of use of these agents, although their beneficial effects are known for long time. Furthermore, the effect of expression or function of Anti-inflammatory action by decreasing the number and density of inflamed acini Wolfgang Glienke et al. 54 
4-Hydroxytamoxifen
Induces apoptosis in human prostate stromal cells
Abbreviations: BP, benzopyran; SERM, selective estrogen receptor modulator. 
Toremifene
In randomized study of 514 men with high-grade PIN, toremifene decreased incidence of prostate cancer by 1 year Abbreviations: ER, estrogen receptor; GnRH, gonadotropin-releasing hormone; PIN, prostatic intraepithelial neoplasia; SERM, selective estrogen receptor modulator.
Selective estrogen receptor modulators M Garg et al ER splice variants and mutations on prostate growth has not been fully understood. 68, 69 ERs may exert both ligand-dependant and -independent activities through genomic and non-genomic pathways. 70, 71 Although these factors may be more crucial in prostate cancer as compared with BPH, these are the certain aspects in estrogen signaling and transcription that require further investigation and research.
Nevertheless, since the discovery of ERb in 1996, development of newer more selective ERb ligands has been a field of active research, and great efforts are going on in this field. 58, 72, 73 With the advancement in techniques, several different mechanisms have been used to identify and create the ERb-selective ligands; for example, Neubauer et al. 74 developed a ERb agonist, which is a inhibitor of prostate growth but has no action on the immune system, while a ERb agonist, which has immune suppressant property without effecting the prostate, was described by Elloso et al. 75 Structural core of known ERb-selective ligands are modified to new compounds with greater selectivity and/or potency, such as isoflavone core structure of genistein. 76 By modifications of the phenolic hydroxyl groups or nitrile groups of ER 77 or by using cells with stably integrated estrogen-responsive element genes, new better molecules may be developed. Also it is now known that ligand binding does not always correlate directly with transcriptional activity, and ER ligands may be receptor subtype selective in either concentration-dependent manner or at the transcriptional level. With these aspects in mind, future development of SERMs or b-selective ligands may be designed with dimer selectivity as well as tissue and subtype selectivity. 78 Additional obstacle in BPH study is the lack of ideal experimental model for BPH. Some animals such as dogs, mouse and rodents have prostate that is hormone responsive and thus suitable in BPH research, although their prostate anatomy varies significantly from that of humans. 79 As such, bladder outlet obstruction resulting from BPH has been insufficiently described in these models. But with the genetic manipulations and advancements in molecular altered pathways, some of these problems have been tackled and transgenic animal models have been developed and utilized. 80 Nicholson et al. 81 recently described a model of BPH and bladder outlet obstruction induced in mice with testosterone (T) and 17b-estradiol (E(2)) combination, and found that this model is suitable for better understanding molecular mechanisms of BPH. Nevertheless, there is definite need of novel and genetically suitable models that help in better understanding of basic mechanisms and development of more effective therapies for BPH.
FUTURE PROSPECTS
Recent progress in the experimental studies for the use of SERMs in treating prostatic diseases is highly encouraging. Tamoxifen can induce apoptosis in human prostate stromal cells. 82 A selective ERb agonist 8b-VE2 induces apoptosis in different prostatic cells in aromatase knockout mice independent of androgens. 54 There are myriads of in vivo and in vitro studies, which confirm the potentials of ER modulators such as toremifene, raloxifene and tamoxifene in inhibiting the proliferation of prostatic epithelial cells and stromal cells, and inhibiting ER activity. 82 Although limited clinical trials of the SERMS in human BPH have been carried till now, its potential for use in prostate diseases can be evident from the animal studies. 83 Tamoxifen resulted in decreased prostate volume in seven beagles with spontaneous BPH. 84 Gonzalez 85 did a randomized trial study in dogs with BPH and showed that there was a 28.5% decrease in prostate volume in the tamoxifen group compared with placebo.
Negative concerns about the use of these drugs in prostate diseases are further negated by ongoing trials and clinical studies on prostate cancer. In a double-blind, phase III study, toremifene in 80 mg doses significantly reduced the incidence of vertebral fractures in men with prostate cancer on androgendeprivation therapy compared with the placebo group. Although thromboembolic events were more frequent, there was a significant improvement in bone mineral density and serum lipid profile in toremifene group. 86 Although in an another phase III randomized double-blind study of 3 years, in which 1590 patients with high-grade prostatic intraepithelial neoplasia were randomized to receive 20 mg toremifene or placebo, the toremifene was not found to decrease the incidence of prostate cancer compared with that of placebo. 87 These preliminary studies indicate that SERMs are well tolerated in men, and have been shown to even ameliorate the side effects of androgen ablation therapy in men with prostate cancer. 86, 88 Because of the continuous increment in our understanding of behavior of ER in a tissue-selective manner and with the developments of newer more specific SERMs and other b-slective ligands, in future, these drugs may become integral part of treatment regime of BPH therapy.
CONCLUSION
With the discovery of ERb-specific SERMs, our knowledge about the basic pathophysiology and underlying cellular signaling mechanism has been potentiated and this has opened up new pathways in pharmacological management of BPH. There are various preclinical studies in literature that support the rationale for evaluation of clinical application of SERM alone or in combination with existing androgen blockade for the management of BPH. ERb appears to mediate beneficial effects by favorably altering the growth factor milieu, and exerting antiproliferative, anti-inflammatory and pro-apoptotic effects.
